Amedeo Smart

Free Medical Literature Service


 

Amedeo

Colorectal Neoplasms

  Free Subscription

Articles published in
J Clin Oncol
    July 2024
  1. KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al
    Development and Implementation of a Digital Quality Measure of Emergency Cancer Diagnosis.
    J Clin Oncol. 2024;42:2506-2515.
    >> Share

  2. CHLEBOWSKI RT, Aragaki AK, Pan K, Luo J, et al
    Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial.
    J Clin Oncol. 2024 Jul 19:JCO2302092. doi: 10.1200/JCO.23.02092.
    >> Share

  3. JAIN A, Lau NS
    Liver Transplantation in Colorectal Cancer With Unresectable Liver Metastases: Disease Biology Cannot Be Ignored.
    J Clin Oncol. 2024 Jul 8:JCO2400619. doi: 10.1200/JCO.24.00619.
    >> Share

    June 2024
  4. NOWAK JA, Twombly T, Ma C, Shi Q, et al
    Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Clin Oncol. 2024 Jun 18:JCO2301680. doi: 10.1200/JCO.23.01680.
    >> Share

  5. ANTONIOTTI C, Rossini D, Pietrantonio F, Salvatore L, et al
    Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
    J Clin Oncol. 2024 Jun 12:JCO2302728. doi: 10.1200/JCO.23.02728.
    >> Share

  6. KAWAZOE A, Xu RH, Garcia-Alfonso P, Passhak M, et al
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
    J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736.
    >> Share

  7. BUTT J, Epplein M
    Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers.
    J Clin Oncol. 2024;42:1865-1867.
    >> Share

    May 2024

  8. Erratum: Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial.
    J Clin Oncol. 2024 May 22:JCO2400997. doi: 10.1200/JCO.24.00997.
    >> Share

    April 2024

  9. Erratum: Predicting Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery: Real-World Data From the International GOSAFE Study.
    J Clin Oncol. 2024 Apr 30:JCO2400763. doi: 10.1200/JCO.24.00763.
    >> Share

  10. HU H, Zhang J, Li Y, Wang X, et al
    Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
    J Clin Oncol. 2024 Apr 2:JCO2301889. doi: 10.1200/JCO.23.01889.
    >> Share

  11. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
    Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
    J Clin Oncol. 2024;42:1098-1101.
    >> Share

    March 2024
  12. GALLOIS C, Shi Q, Pederson LD, Andre T, et al
    Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
    J Clin Oncol. 2024 Mar 28:JCO2301326. doi: 10.1200/JCO.23.01326.
    >> Share

  13. GAO Z, Zhu Z, Li K
    Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.
    J Clin Oncol. 2024;42:1088.
    >> Share

  14. MEHTSUN WT, Gupta S
    Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer-We Must Do Better.
    J Clin Oncol. 2024 Mar 15:JCO2302186. doi: 10.1200/JCO.23.02186.
    >> Share

  15. DOMINGO E, Kelly C, Hay J, Sansom O, et al
    Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
    J Clin Oncol. 2024 Mar 14:JCO2301648. doi: 10.1200/JCO.23.01648.
    >> Share

  16. LORIA A, Ramsdale EE, Aquina CT, Cupertino P, et al
    From Clinical Trials to Practice: Anticipating and Overcoming Challenges in Implementing Watch-and-Wait for Rectal Cancer.
    J Clin Oncol. 2024;42:876-880.
    >> Share

  17. FOKAS E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, et al
    Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited.
    J Clin Oncol. 2024;42:872-875.
    >> Share

  18. BATTAGLIN F, Ou FS, Qu X, Hochster HS, et al
    HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
    J Clin Oncol. 2024 Mar 8:JCO2301507. doi: 10.1200/JCO.23.01507.
    >> Share

  19. SHAH SC, Camargo MC, Lamm M, Bustamante R, et al
    Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort.
    J Clin Oncol. 2024 Mar 1:JCO2300703. doi: 10.1200/JCO.23.00703.
    >> Share

    February 2024
  20. RAHBARI NN, Biondo S, Frago R, Feisst M, et al
    Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
    J Clin Oncol. 2024 Feb 27:JCO2301540. doi: 10.1200/JCO.23.01540.
    >> Share

  21. VERHEIJ FS, Omer DM, Williams H, Lin ST, et al
    Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.
    J Clin Oncol. 2024;42:500-506.
    >> Share

  22. CHEN L, Wang Y, Cai C, Ding Y, et al
    Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
    J Clin Oncol. 2024 Feb 5:JCO2301080. doi: 10.1200/JCO.23.01080.
    >> Share

    January 2024
  23. PINTO C, Orlandi A, Normanno N, Maiello E, et al
    Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study.
    J Clin Oncol. 2024 Jan 5:JCO2301021. doi: 10.1200/JCO.23.01021.
    >> Share

  24. DOSSA F, Baxter NN
    Understanding Tradeoffs in the Treatment of Rectal Cancer From the Patient Perspective.
    J Clin Oncol. 2024;42:120-121.
    >> Share

  25. EL SISSY C, Kirilovsky A, Lagorce Pages C, Marliot F, et al
    International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.
    J Clin Oncol. 2024;42:70-80.
    >> Share

    December 2023
  26. STEBBING J, Schlechter BL
    Genes and Race in Colon Cancer.
    J Clin Oncol. 2023 Dec 7:JCO2302094. doi: 10.1200/JCO.23.02094.
    >> Share

    November 2023
  27. INNOCENTI F, Mu W, Qu X, Ou FS, et al
    DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
    J Clin Oncol. 2023 Nov 22:JCO2300825. doi: 10.1200/JCO.23.00825.
    >> Share

  28. DE GRAMONT A, Figer A, Seymour M, Homerin M, et al
    Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer.
    J Clin Oncol. 2023;41:5080-5089.
    >> Share


  29. JCO Flashback: Exploring an Effective Drug Combination for Colorectal Cancer (2000).
    J Clin Oncol. 2023;41:5079.
    >> Share

  30. MAYER RJ
    Flashback Foreword: Oxaliplatin Plus LV5FU2 in Colorectal Cancer.
    J Clin Oncol. 2023;41:5077-5078.
    >> Share

  31. DUVIVIER HL, Rothe M, Mangat PK, Garrett-Mayer E, et al
    Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    J Clin Oncol. 2023;41:5140-5150.
    >> Share

  32. HEYMER EJ, Jozwiak K, Kremer LC, Winter DL, et al
    Cumulative Absolute Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors: A PanCareSurFup Study.
    J Clin Oncol. 2023 Nov 16:JCO2300452. doi: 10.1200/JCO.23.00452.
    >> Share

  33. NOGUEIRA LM, May FP, Yabroff KR, Siegel RL, et al
    Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer in the United States.
    J Clin Oncol. 2023 Nov 8:JCO2300539. doi: 10.1200/JCO.23.00539.
    >> Share

  34. ZWANENBURG ES, El Klaver C, Wisselink DD, Punt CJA, et al
    Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial.
    J Clin Oncol. 2023 Nov 3:JCO2202644. doi: 10.1200/JCO.22.02644.
    >> Share

    October 2023
  35. IOFFE D, Dotan E
    Evidence-Based Care of Older Adults With Metastatic Colorectal Cancer: Insights From Landmark Clinical Trials.
    J Clin Oncol. 2023 Oct 19:JCO2301337. doi: 10.1200/JCO.23.01337.
    >> Share

  36. HALL WA, Li J, You YN, Gollub MJ, et al
    Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.
    J Clin Oncol. 2023;41:4643-4651.
    >> Share

  37. WANG G, Liu Z
    Alcohol Intake Associated With Increased Risk of Early-Onset Colorectal Cancer.
    J Clin Oncol. 2023 Oct 2:JCO2301548. doi: 10.1200/JCO.23.01548.
    >> Share

    September 2023

  38. Erratum: FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
    J Clin Oncol. 2023 Sep 12:JCO2301858. doi: 10.1200/JCO.23.01858.
    >> Share

    August 2023
  39. RUPPERT R, Junginger T, Kube R, Strassburg J, et al
    Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study.
    J Clin Oncol. 2023;41:4025-4034.
    >> Share

  40. LONARDI S, Rasola C, Lobefaro R, Rossini D, et al
    Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation.
    J Clin Oncol. 2023 Aug 3:JCO2300506. doi: 10.1200/JCO.23.00506.
    >> Share

    July 2023
  41. SALTZ LB, Clarke S, Diaz-Rubio E, Scheithauer W, et al
    Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study.
    J Clin Oncol. 2023;41:3663-3669.
    >> Share

  42. GIANTONIO BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, et al
    Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200.
    J Clin Oncol. 2023;41:3670-3675.
    >> Share

  43. O'REILLY EM
    Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer.
    J Clin Oncol. 2023;41:3661-3662.
    >> Share

  44. BASCH E, Dueck AC, Mitchell SA, Mamon H, et al
    Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
    J Clin Oncol. 2023;41:3724-3734.
    >> Share

  45. TOURNIGAND C, Andre T, Achille E, Lledo G, et al
    FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study.
    J Clin Oncol. 2023;41:3469-3477.
    >> Share

  46. GOLDBERG RM, Sargent DJ, Morton RF, Fuchs CS, et al
    A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer.
    J Clin Oncol. 2023;41:3461-3468.
    >> Share

  47. VENOOK AP
    Flashback Foreword: IFL/FOLFOX/IROX in Advanced Colorectal Cancer and FOLFIRI and FOLFOX6 in Colorectal Cancer.
    J Clin Oncol. 2023;41:3459-3460.
    >> Share

    June 2023
  48. MONTRONI I, Ugolini G, Saur NM, Rostoft S, et al
    Predicting Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery: Real-World Data From the International GOSAFE Study.
    J Clin Oncol. 2023 Jun 30:JCO2202195. doi: 10.1200/JCO.22.02195.
    >> Share

  49. LORIA A, Fleming FJ
    Restoration of Quality of Life and Functional Recovery After Colorectal Cancer Surgery in Older Adults.
    J Clin Oncol. 2023 Jun 30:JCO2301066. doi: 10.1200/JCO.23.01066.
    >> Share

  50. IRAJIZAD E, Fahrmann JF, Marsh T, Vykoukal J, et al
    Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.
    J Clin Oncol. 2023 Jun 28:JCO2202424. doi: 10.1200/JCO.22.02424.
    >> Share

  51. STINTZING S, Heinrich K, Tougeron D, Modest DP, et al
    FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF(V600E)-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
    J Clin Oncol. 2023 Jun 23:JCO2201420. doi: 10.1200/JCO.22.01420.
    >> Share

  52. AMADO RG, Wolf M, Peeters M, Van Cutsem E, et al
    Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.
    J Clin Oncol. 2023;41:3278-3286.
    >> Share


  53. JCO Flashback: Predictive Value of KRAS Mutations on the Outcomes of Panitumumab Monotherapy in Colorectal Cancer.
    J Clin Oncol. 2023;41:3277.
    >> Share

  54. KO AH
    Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer.
    J Clin Oncol. 2023;41:3275-3276.
    >> Share

  55. PARK JH, Hong JY, Shen JJ, Han K, et al
    Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study.
    J Clin Oncol. 2023;41:3363-3373.
    >> Share

  56. SEAGLE HM, Keller SR, Tavtigian SV, Horton C, et al
    Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer.
    J Clin Oncol. 2023 Jun 15:JCO2202378. doi: 10.1200/JCO.22.02378.
    >> Share

  57. JIN EH, Han K, Shin CM, Lee DH, et al
    Sex and Tumor-Site Differences in the Association of Alcohol Intake With the Risk of Early-Onset Colorectal Cancer.
    J Clin Oncol. 2023 Jun 14:JCO2201895. doi: 10.1200/JCO.22.01895.
    >> Share

  58. STINCHCOMBE TE
    Encorafenib and Binimetinib: A New Treatment Option for BRAF(V600E)-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 4:JCO2300983. doi: 10.1200/JCO.23.00983.
    >> Share

    May 2023
  59. DOTTORINI L, Petrelli F, Ghidini A, Rea CG, et al
    Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?
    J Clin Oncol. 2023 May 15:JCO2300354. doi: 10.1200/JCO.23.00354.
    >> Share

    April 2023
  60. LUDFORD K, Ho WJ, Thomas JV, Raghav KPS, et al
    Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.
    J Clin Oncol. 2023;41:2181-2190.
    >> Share

  61. CIOMBOR KK, Eng C
    Immunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?
    J Clin Oncol. 2023;41:2138-2140.
    >> Share

  62. STAHLER A, Hoppe B, Na IK, Keilholz L, et al
    Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
    J Clin Oncol. 2023 Apr 5:JCO2202582. doi: 10.1200/JCO.22.02582.
    >> Share

  63. VIKAS P, Messersmith H, Compton C, Sholl L, et al
    Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline.
    J Clin Oncol. 2023;41:1943-1948.
    >> Share

    February 2023
  64. HOTCA A, Goodman KA
    Trends in Anal Cancer: Leveraging Public Health Efforts to Improve Cancer Care.
    J Clin Oncol. 2023;41:1180-1182.
    >> Share

  65. VAN CUTSEM E, Taieb J, Yaeger R, Yoshino T, et al
    ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer.
    J Clin Oncol. 2023 Feb 10:JCO2201693. doi: 10.1200/JCO.22.01693.
    >> Share

  66. KAMIHARA J, Collins NB
    Learning About Mismatch Repair From a Rare Cancer Syndrome: A LOGICal Step Forward.
    J Clin Oncol. 2023;41:727-731.
    >> Share

  67. CHUNG J, Negm L, Bianchi V, Stengs L, et al
    Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.
    J Clin Oncol. 2023;41:766-777.
    >> Share

    January 2023
  68. MORTON D, Seymour M, Magill L, Handley K, et al
    Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.
    J Clin Oncol. 2023 Jan 19:JCO2200046. doi: 10.1200/JCO.22.00046.
    >> Share

  69. HALL WA, Smith JJ
    Achieving a Cure Without Total Mesorectal Excision in Rectal Adenocarcinoma.
    J Clin Oncol. 2023;41:173-180.
    >> Share

  70. SOCHA J, Zolciak-Siwinska A, Bujko K
    Radio- or Chemotherapy Dose Escalation for Organ Preservation in Rectal Cancer?
    J Clin Oncol. 2023;41:417.
    >> Share

  71. KAZI M, Saklani A
    Total Neoadjuvant Therapy for All Rectal Cancers: Is This the Way Ahead of the OPRA Trial?
    J Clin Oncol. 2023;41:415-416.
    >> Share

  72. SUTCUOGLU O, Rustamova Cennet N, Ozet A, Ozdemir N, et al
    Interpretation of the OPRA Study: Are Our Criteria Reliable Enough to Recommend Watch and Wait?
    J Clin Oncol. 2023;41:416-417.
    >> Share

  73. KENNECKE HF, O'Callaghan CJ, Loree JM, Moloo H, et al
    Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results.
    J Clin Oncol. 2023;41:233-242.
    >> Share

  74. YU Y, Shi Q, Chen H
    Acquired Genomic Alterations From First-Line Anti-EGFR Chemotherapy in Advanced Colorectal Cancer: Improving Study Design and Data Analysis.
    J Clin Oncol. 2023 Jan 3:JCO2202296. doi: 10.1200/JCO.22.02296.
    >> Share

    December 2022
  75. SUTCUOGLU O, Ozet A, Yazici O, Ozdemir N, et al
    Could the STELLAR Study Change the Rectal Cancer Treatment Algorithm?
    J Clin Oncol. 2022;40:4027.
    >> Share

  76. YUKSEL BC
    Chemoradiotherapy in Locally Advanced Rectal Cancer: Surgeon Perspective.
    J Clin Oncol. 2022;40:4029.
    >> Share

  77. NEGRI F, Aschele C
    Unconsolidated Results of Consolidation Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer.
    J Clin Oncol. 2022;40:4028.
    >> Share

    November 2022
  78. DAMGACIOGLU H, Lin YY, Ortiz AP, Wu CF, et al
    State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States.
    J Clin Oncol. 2022 Nov 28:JCO2201390. doi: 10.1200/JCO.22.01390.
    >> Share

  79. LEE S, Ma C, Shi Q, Kumar P, et al
    Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
    J Clin Oncol. 2022 Nov 11:JCO2201637. doi: 10.1200/JCO.22.01637.
    >> Share

  80. PARSEGHIAN CM, Sun R, Woods M, Napolitano S, et al
    Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy.
    J Clin Oncol. 2022 Nov 9:101200JCO2201423. doi: 10.1200/JCO.22.01423.
    >> Share

    October 2022
  81. GALLOIS C, Shi Q, Meyers JP, Iveson T, et al
    Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
    J Clin Oncol. 2022 Oct 28:JCO2102726. doi: 10.1200/JCO.21.02726.
    >> Share

  82. MORRIS VK, Kennedy EB, Baxter NN, Benson AB 3rd, et al
    Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
    J Clin Oncol. 2022 Oct 17:JCO2201690. doi: 10.1200/JCO.22.01690.
    >> Share

    September 2022
  83. RAGHAV K, Ou FS, Venook AP, Innocenti F, et al
    Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
    J Clin Oncol. 2022 Sep 6:JCO2200365. doi: 10.1200/JCO.22.00365.
    >> Share

    August 2022
  84. TOPHAM JT, O'Callaghan CJ, Feilotter H, Kennecke HF, et al
    Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.
    J Clin Oncol. 2022 Aug 25:JCO2200364. doi: 10.1200/JCO.22.00364.
    >> Share

  85. AREF A, Abdalla A
    Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Induction or Consolidation Chemotherapy?
    J Clin Oncol. 2022;40:2515-2519.
    >> Share

  86. GARCIA-AGUILAR J, Patil S, Gollub MJ, Kim JK, et al
    Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
    J Clin Oncol. 2022;40:2546-2556.
    >> Share

  87. OU SI, Janne PA, Leal TA, Rybkin II, et al
    First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1).
    J Clin Oncol. 2022;40:2530-2538.
    >> Share

  88. BROWN JC, Ma C, Shi Q, Fuchs CS, et al
    Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Clin Oncol. 2022 Aug 9:JCO2200171. doi: 10.1200/JCO.22.00171.
    >> Share

    July 2022
  89. MALLA M, Loree JM, Kasi PM, Parikh AR, et al
    Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
    J Clin Oncol. 2022 Jul 15:JCO2102615. doi: 10.1200/JCO.21.02615.
    >> Share

    June 2022
  90. KIM ST, Kim SY, Lee J, Yun SH, et al
    Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.
    J Clin Oncol. 2022 Jun 30:JCO2102962. doi: 10.1200/JCO.21.02962.
    >> Share

  91. ROSSINI D, Antoniotti C, Lonardi S, Pietrantonio F, et al
    Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study b
    J Clin Oncol. 2022 Jun 6:JCO2200839. doi: 10.1200/JCO.22.00839.
    >> Share

  92. CIOMBOR KK, Strickler JH, Bekaii-Saab TS, Yaeger R, et al
    BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape.
    J Clin Oncol. 2022 Jun 1:JCO2102541. doi: 10.1200/JCO.21.02541.
    >> Share

  93. RAPHAEL MJ, Karanicolas PJ
    Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?
    J Clin Oncol. 2022 Jun 1:JCO2102505. doi: 10.1200/JCO.21.02505.
    >> Share

  94. JIN Z, Sinicrope FA
    Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
    J Clin Oncol. 2022 Jun 1:JCO2102691. doi: 10.1200/JCO.21.02691.
    >> Share

  95. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    >> Share

  96. ENG C, Ciombor KK, Cho M, Dorth JA, et al
    Anal Cancer: Emerging Standards in a Rare Rare Disease.
    J Clin Oncol. 2022 Jun 1:JCO2102566. doi: 10.1200/JCO.21.02566.
    >> Share

    May 2022
  97. JIN J, Tang Y, Hu C, Jiang LM, et al
    Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).
    J Clin Oncol. 2022;40:1681-1692.
    >> Share

  98. YOSHINO T, Oki E, Misumi T, Kotaka M, et al
    Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
    J Clin Oncol. 2022 May 5:JCO2102628. doi: 10.1200/JCO.21.02628.
    >> Share

    March 2022
  99. SUTCUOGLU O, Ulas Kahya B, Ozdemir N, Yazici O, et al
    Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
    J Clin Oncol. 2022 Mar 29:JCO2200047. doi: 10.1200/JCO.22.00047.
    >> Share

  100. MORANO F, Raimondi A, Pagani F, Lonardi S, et al
    Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
    J Clin Oncol. 2022 Mar 8:JCO2102583. doi: 10.1200/JCO.21.02583.
    >> Share

    February 2022
  101. COPUR MS, Kelly J, Tun SM
    Treatment Break Versus Maintenance in Metastatic Colorectal Cancer.
    J Clin Oncol. 2022 Feb 22:JCO2102420. doi: 10.1200/JCO.21.02420.
    >> Share

    January 2022
  102. CHENG E, Ou FS, Ma C, Spiegelman D, et al
    Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).
    J Clin Oncol. 2022 Jan 7:JCO2101784. doi: 10.1200/JCO.21.01784.
    >> Share

    December 2021
  103. BAXTER NN, Kennedy EB, Bergsland E, Berlin J, et al
    Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
    J Clin Oncol. 2021 Dec 22:JCO2102538. doi: 10.1200/JCO.21.02538.
    >> Share

  104. FONTANA E, Meyers J, Sobrero A, Iveson T, et al
    Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
    J Clin Oncol. 2021;39:4009-4019.
    >> Share

  105. MULCAHY MF, Mahvash A, Pracht M, Montazeri AH, et al
    Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
    J Clin Oncol. 2021;39:3897-3907.
    >> Share

    November 2021
  106. PAN M, Jiang C, Tse P, Achacoso N, et al
    TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer.
    J Clin Oncol. 2021 Nov 29:JCO2102014. doi: 10.1200/JCO.21.02014.
    >> Share

    October 2021
  107. LENZ HJ, Van Cutsem E, Luisa Limon M, Wong KYM, et al
    First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    J Clin Oncol. 2021 Oct 12:JCO2101015. doi: 10.1200/JCO.21.01015.
    >> Share

    September 2021
  108. BOZKURT DUMAN B, Cil T
    Do the Survival Data of Primary Tumor Resection Provide Sufficient Data Without Considering the Tumor Sidedness, Predictive Biomarkers, and Biologic Agents?
    J Clin Oncol. 2021;39:2970.
    >> Share

  109. RAYSON D
    Cardio-Oncology.
    J Clin Oncol. 2021;39:2962-2963.
    >> Share

  110. DURNO C, Ercan AB, Bianchi V, Edwards M, et al
    Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance.
    J Clin Oncol. 2021;39:2779-2790.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016